title: Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects.
abstract: BACKGROUND
  Use of sulphasalazine in ulcerative colitis patients is hampered by a variety of side-effects, including male infertility. 5-aminosalicylic acid is better tolerated and has been increasingly used to treat patients intolerant/allergic to sulphasalazine but it may also be associated with side-effects.
  
  
  OBJECTIVE
  To evaluate tolerance of long-term treatment with sulphasalazine and 5-aminosalicylic acid in ulcerative colitis.
  
  
  METHODS
  Side-effects to sulphasalazine (2-3 g/day) and 5-aminosalicylic acid (1.2-2.4 g/day) were recorded in 685 patients: 410 patients received only sulphasalazine, 130 only 5-aminosalicylic acid, and 145 both drugs. In patients with side-effects to sulphasalazine, a desensitisation protocol (rechallenge) was attempted to improve tolerance, and patients still presenting side-effects after desensitisation were switched to 5-aminosalicylic acid. Male fertility was also assessed in 42 males on sulphasalazine and on 5-aminosalicylic acid.
  
  
  RESULTS
  Side-effects were observed in 110/555 patients (20%) on sulphasalazine and in 18/275 patients (6.5%) on 5-aminosalicylic acid during a median period of follow-up of 7 and 5 years, respectively. Desensitisation was achieved in 40% of patients intolerant to sulphasalazine. 5-aminosalicylic acid intake induced side-effects in 2/130 patients (1.5%) who had not taken sulphasalazine before versus 4/91 patients (4%) tolerating sulphasalazine and 12/54 patients (22%) intolerant/allergic to sulphasalazine, the difference in incidence of side-effects in the two latter groups being statistically significant (4.4% vs 20.8%, p=0. 001). Fertility was found to be affected in all patients on sulphasalazine but improved when put onto 5-aminosalicylic acid.
  
  
  CONCLUSIONS
  5-aminosalicylic acid should be considered the drug of choice in the treatment of ulcerative colitis bearing in mind that intolerance or allergy may occur in a few patients also on this drug.
authors.affiliation: Department of Clinical Sciences, La Sapienza University, Rome, Italy.
authors.forename: M C
authors.initials: MC
authors.lastname: Di Paolo
authors.forename: O A
authors.initials: OA
authors.lastname: Paoluzi
authors.forename: R
authors.initials: R
authors.lastname: Pica
authors.forename: F
authors.initials: F
authors.lastname: Iacopini
authors.forename: P
authors.initials: P
authors.lastname: Crispino
authors.forename: M
authors.initials: M
authors.lastname: Rivera
authors.forename: G
authors.initials: G
authors.lastname: Spera
authors.forename: P
authors.initials: P
authors.lastname: Paoluzi
mesh_terms: D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003888:Desensitization, Immunologic; D004415:Dyspepsia / Q000139:chemically induced; D005500:Follow-Up Studies; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007248:Infertility, Male / Q000139:chemically induced*; D008297:Male; D019804:Mesalamine / Q000009:adverse effects* / Q000627:therapeutic use; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D012460:Sulfasalazine; D019804:Mesalamine